Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc.
Company typePublic
Industry
Founded1988; 36 years ago (1988)
Founders
HeadquartersTarrytown, New York, U.S.
Area served
Global
Key people
  • Leonard Schleifer (CEO)
  • George Yancopoulos (CSO)
RevenueIncrease US$13.12 billion (2023)
Decrease US$4.05 billion (2023)
Decrease US$3.95 billion (2023)
Total assetsIncrease US$33.08 billion (2023)
Total equityIncrease US$25.97 billion (2023)
Number of employees
13,450 (2023)
Websitewww.regeneron.com Edit this at Wikidata
Footnotes / references
[1]

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.[2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

  1. ^ "Regeneron Pharmaceuticals, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 5, 2024.
  2. ^ Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. Archived from the original on March 16, 2014. Retrieved March 22, 2014.Open access icon